VanadiumCorp Resource Inc. has filed for final TSX Venture Exchange approval of its $635,000 non-brokered private placement financing, issuing over 5.2 million units. Each unit includes one common share and one warrant exercisable at $0.22 for two years, with potential acceleration if share prices rise. The funds will support working capital and general corporate purposes. Two investors became insiders through this financing, which is expected to be exempt from certain regulatory approvals. This move supports VanadiumCorp's ongoing development of its mineral projects and proprietary extraction technology for vanadium and related metals.
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
BlackRock reported quarterly earnings per share of $13.91, surpassing analyst estimates of $12.69, and revenue of $7.08 billion, exceeding expectations of $6.73 billion. The company’s assets under management reached a record $15.3 trillion, a 22% inc...
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
